NCYT:LON
Novacyt SA
GBX 39.50
arrow_downward
-0.25%(-0.100) 1D
Oct 16, 4:35:25 PM GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NCYT...
Open
GBX 39.60
High
GBX 39.68
Low
GBX 39.20
Mkt. cap
33.99M
Avg. vol.
102.63K
Volume
12.22K
52-wk high
GBX 86.00
52-wk low
GBX 26.60
Shares outstanding
37.66M
No. of employees
228
Open
GBX 39.60
High
GBX 39.68
Low
GBX 39.20
Mkt. cap
33.99M
Avg. vol.
102.63K
Volume
12.22K
52-wk high
GBX 86.00
52-wk low
GBX 26.60
Shares outstanding
37.66M
No. of employees
228
News stories
From web sources and news partners
Investopedia
·
37 minutes ago
Nasdaq Poised to End Run of Weekly Gains
ChartMill
·
1 hour ago
S&P 500 Gap Downs on October 16: MRNA, TWLO and COHR Lead Declines
StoneX
·
36 minutes ago
S&P 500 Forecast: SPX set for a weekly decline led lower by tech as AI worries linger
FXEmpire
·
17 minutes ago
Nasdaq and S&P Index: AI Selling Deepens as Dow Holds Up on Rotation
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA